Novo presents CagriSema visceral fat and bone data at EASD 2026
Phase 3 REIMAGINE 5 showed 12.4% weight loss at 60 weeks versus 9.1% for tirzepatide, while a hemophilia filing slipped to 2027 on plant remediation.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 3 04:10 ETSource: AD HOC NEWS
The wire
- 01At EASD 2026 Novo Nordisk reported CagriSema shifts in brain response to food cues, reduced visceral fat and stable bone health in adults with type 2 diabetes; REDEFINE 9 showed 21.0% weight loss versus 2% on placebo.
- 02The cagrilintide-semaglutide combination is being positioned against tirzepatide on comorbidities, not weight alone, which matters for formulary and prescribing conversations.
- 03FDA extended review of Novo's hemophilia drug Denecimig over manufacturing remediation with no new decision date; the company also licensed Hengrui's oral GLP-1/GIP agonist HRS-1596 for $300 million upfront, up to $2.6 billion.
From the source
Read at ad-hoc-news.deNovo Nordisk's CagriSema Data Lands as FDA Plant Fixes Push Denecimig Launch to 2027
Fresh clinical evidence for Novo Nordisk's dual-action obesity candidate CagriSema emerged this week at the EASD 2026 diabetes conference, where researchers presented findings showing shifts in how the brain responds to visual food cues, a reduction in fat surrounding abdominal organs, and preliminary signals that bone health held steady during weight loss in adults with type 2 diabetes.
